Literature DB >> 21084664

Efficient lung recruitment of respiratory syncytial virus-specific Th1 cells induced by recombinant bacillus Calmette-Guérin promotes virus clearance and protects from infection.

Kelly M Cautivo1, Susan M Bueno, Claudia M Cortes, Aniela Wozniak, Claudia A Riedel, Alexis M Kalergis.   

Abstract

Infection by the respiratory syncytial virus (RSV) can cause extensive inflammation and lung damage in susceptible hosts due to a Th2-biased immune response. Such a deleterious inflammatory response can be enhanced by immunization with formalin- or UV-inactivated RSV, as well as with vaccinia virus expressing the RSV-G protein. Recently, we have shown that vaccination with rBCG-expressing RSV Ags can prevent the disease in the mouse. To further understand the immunological mechanisms responsible for protection against RSV, we have characterized the T cell populations contributing to virus clearance in mice immunized with this BCG-based vaccine. We found that both CD4(+) and CD8(+) T cells were recruited significantly earlier to the lungs of infected mice that were previously vaccinated. Furthermore, we observed that simultaneous adoptive transfer of CD8(+) and CD4(+) RSV-specific T cells from vaccinated mice was required to confer protection against virus infection in naive recipients. In addition, CD4(+) T cells induced by vaccination released IFN-γ after RSV challenge, indicating that protection is mediated by a Th1 immune response. These data suggest that vaccination with rBCG-expressing RSV Ags can induce a specific effector/memory Th1 immune response consisting on CD4(+) and CD8(+) T cells, both necessary for a fully protective response against RSV. These results support the notion that an effective induction of Th1 T cell immunity against RSV during childhood could counteract the unbalanced Th2-like immune response triggered by the natural RSV infection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21084664     DOI: 10.4049/jimmunol.0903452

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  37 in total

1.  Impaired learning resulting from respiratory syncytial virus infection.

Authors:  Janyra A Espinoza; Karen Bohmwald; Pablo F Céspedes; Roberto S Gómez; Sebastián A Riquelme; Claudia M Cortés; Javier A Valenzuela; Rodrigo A Sandoval; Floria C Pancetti; Susan M Bueno; Claudia A Riedel; Alexis M Kalergis
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-06       Impact factor: 11.205

2.  Insights on the crosstalk between dendritic cells and helper T cells in novel genetic etiology for mendelian susceptible mycobacterial disease.

Authors:  Emma Rey-Jurado; Magdalena S Pizarro-Ortega; Alexis M Kalergis
Journal:  Cell Mol Immunol       Date:  2018-11-07       Impact factor: 11.530

Review 3.  Respiratory syncytial virus vaccine development.

Authors:  Julia L Hurwitz
Journal:  Expert Rev Vaccines       Date:  2011-10       Impact factor: 5.217

4.  Dietary effect on immunological energetics in mice.

Authors:  Sebastián I Martel; Sebastián A Riquelme; Alexis M Kalergis; Francisco Bozinovic
Journal:  J Comp Physiol B       Date:  2014-08-17       Impact factor: 2.200

5.  Stable Expression of Lentiviral Antigens by Quality-Controlled Recombinant Mycobacterium bovis BCG Vectors.

Authors:  Bryan E Hart; Rose Asrican; So-Yon Lim; Jaimie D Sixsmith; Regy Lukose; Sommer J R Souther; Swati D G Rayasam; Joseph W Saelens; Ching-Ju Chen; Sarah A Seay; Linda Berney-Meyer; Leslie Magtanong; Kim Vermeul; Priyadharshini Pajanirassa; Amanda E Jimenez; Tony W Ng; David M Tobin; Steven A Porcelli; Michelle H Larsen; Joern E Schmitz; Barton F Haynes; William R Jacobs; Sunhee Lee; Richard Frothingham
Journal:  Clin Vaccine Immunol       Date:  2015-04-29

6.  Role for Gr-1+ cells in the control of high-dose Mycobacterium bovis recombinant BCG.

Authors:  Michael W Panas; Norman L Letvin
Journal:  Clin Vaccine Immunol       Date:  2014-06-11

Review 7.  A safe and efficient BCG vectored vaccine to prevent the disease caused by the human Respiratory Syncytial Virus.

Authors:  Emma Rey-Jurado; Jorge Soto; Nicolás Gálvez; Alexis M Kalergis
Journal:  Hum Vaccin Immunother       Date:  2017-06-09       Impact factor: 3.452

Review 8.  Progress in respiratory virus vaccine development.

Authors:  Alexander C Schmidt
Journal:  Semin Respir Crit Care Med       Date:  2011-08-19       Impact factor: 3.119

Review 9.  Targeting RSV with vaccines and small molecule drugs.

Authors:  Heather M Costello; William C Ray; Supranee Chaiwatpongsakorn; Mark E Peeples
Journal:  Infect Disord Drug Targets       Date:  2012-04

Review 10.  Induction of protective effector immunity to prevent pathogenesis caused by the respiratory syncytial virus. Implications on therapy and vaccine design.

Authors:  Janyra A Espinoza; Susan M Bueno; Claudia A Riedel; Alexis M Kalergis
Journal:  Immunology       Date:  2014-09       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.